Cytokinetics is a specialty biopharmaceutical company building on its over 25-years of pioneering scientific innovation with intention to create a muscle biology franchise business focused on ...

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb's ...

Cytokinetics (CYTK) announced the launch of EARTH-HCM, an online, open access, interactive public health education tool developed by Cytokinetics in collaboration with leading academic ...

Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. If all goes well, it could be approved by September 2025. Aficamten had favorable Phase 3 data, so it could have ...

Cytokinetics (CYTK) shares rallied 5.4% in the last trading session to close at $45.43. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Portage Biotech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.95, suggesting that its stock price is 5% ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against the other ...

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) were up 4.9% during mid-day trading on Friday . The company traded as high as $44.71 and last traded at $45.20. Approximately ...

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...